The use of new oral anticoagulants in surgery. Part 1

Pasechnik I.N.

doi:https://doi.org/10.17116/hirurgia2016272-75

Pasechnik I.N.

Central State Medical Academy of the Presidential Administration of the Russian Federation

The use of new oral anticoagulants in surgery. Part 1

Authors:

Pasechnik I.N.

More about the authors

Journal: Pirogov Russian Journal of Surgery. 2016;(2): 72‑75

DOI: 10.17116/hirurgia2016272-75

Read: 2397 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Pasechnik IN. The use of new oral anticoagulants in surgery. Part 1. Pirogov Russian Journal of Surgery. 2016;(2):72‑75. (In Russ.)
https://doi.org/10.17116/hirurgia2016272-75

Подписка 2026 Хирургия. Журнал им. Н.И. Пирогова (Pirogov Russian Journal of Surgery)

Использование инфографики авторами научных работ

References:

Загородний Н.В., Бухтин К.М. Применение ривораксабана для профилактики тромбоэмболических осложнений после эндопротезирования крупных суставов в реальной клинической практике в России (по данным проспективного многоцентрового неинтервенционного исследования СОПРАНО). Вестник травматологии и ортопедии им. Н.Н. Приорова. 2015;1:84-90.
Марцевич С.Ю., Навасардян А.Р., Кутишенко Н.П. и др. Оценка динамики назначения антитромботических препаратов у пациентов с фибрилляцией предсердий по данным регистра ПРОФИЛЬ. Кардиоваскулярная терапия и профилактика. 2015;1:35-40.
Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Флебология. 2010;1:3-37.
Рябов Г.А., Пасечник И.Н., Азизов Ю.М. Протеин С. Терапевтический архив. 1989;7:151-153.
Сулимов В.А., Напалков Д.А., Соколова А.А. Сравнительная эффективность и безопасность новых пероральных антикоагулянтов. Рациональная фармакотерапия в кардиологии. 2013;4:433-438.
Agnelli G, Buller HR, Cohen A et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699-708.
Agnelli G, Buller HR, Cohen A et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;368:799-808.
Camm AJ, Lip GY, Caterina R et al. ESC Committee for Practice Guidelines (CPG): 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33:2719-2747.
Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
Eriksson BI, Dahl OE, Rosencher N et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolizm after total hip replacement: a randomised double-blind non-inferior trial. Lancet. 2007;370:949-956.
Eriksson BI, Borris LC, Friedman RJ et al. Rivoraxaban versus enoxaparin for thromboprophylaxix after hip arthroplasty. N Engl J Med. 2008;358:2765-2775.
Ginsberg JS, Davidson BL, Comp PC et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24:1-9.
Glader EL, Sjolander M, Eriksson M, Lundberg M. Persistent use of secondary preventative drugs declines rapidly during the first two years after stroke. Stroke. 2010;41:397-401.
Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-867.
Hirsh J, Fuster V, Ansell J et al. AHA/ACC. Expert Consensus Document on Warfarin Therapy American Heart Asocoation/American College of Cardiology. Foundation Guide to Warfarin Therapy. JACC. 2003;41:633-652.
Kubitza D, Haas S. Novel factor Xa inhibitor for prevention and treatment of thromboembolic diseases. Expert Opin Investig Drugs. 2006;15:843-855.
Lassen MR, Agelo W, Boris LS et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776-2786.
Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost. 2003;1:1504-1514.
Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.
Riva N, Ageno W. Which patients with venous thromboembolism should receive non-vitamin K antagonist oral anticoagulants? The majority. Blood Transfus. 2015;13:181-183.
Schwartz UI, Ritchie MD, Bradford Y et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008;36:999-1008.